Exact Sciences Drops $75M on Blood Test Like It’s Hot
In a move that screams 'We want it first or we want it all,' Exact Sciences is shelling out a whopping $75 million to snag exclusive rights to a blood-based 'liquid biopsy' from rival Freenome. Because nothing says friendly competition like locking down your neighbor's science project. To quote the deal, Exact Sciences is paying for 'exclusive rights'—so if you wanted a sneak peek at this fancy blood test, tough luck. Apparently, in the world of medical high-stakes poker, $75 million is just the ante.
Share the Story
Exact Sciences just bought a blood test like it was the last Pumpkin Spice Latte. Exclusive rights for $75M proves medicine now prefers monopolies over miracles. Thanks, capitalism!
Nothing says friendship like a $75 million handshake to keep your rival’s blood test under lock and key. Science today: where billion-dollar block parties happen in lab coats.
Exact Sciences is basically the kid who snatches the shared toy and screams 'Mine!' but with $75 million. Blood tests have never been so possessive.
Source: Statnews | Published: 8/6/2025 | Author: Jonathan Wosen
More Articles in Health
Trump Promises Retirement Plan That Matches Generosity of Federal Workers’ Excuses
Trump Calls Supreme Court 'Unfortunate,' Then Hits Economy with ‘Better’ 10% Global Tariff
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Mom Skips Junior Year Exams, Swaps Algebra for Penguins in Antarctica
America Solves Fentanyl Crisis by Inventing Pink Cocaine Zombie Apocalypse
French Obesity Rate Mystifies US After Cheese, Wine, Bread Diet Approved
Woman Waited Years to Wear Favorite Clothes; Life Finally Happened, Clothes Revolted
RFK Jr. Promises To Investigate Ultra-Processed Junk Food but Won't Regulate It
